Comparison
While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, MOTS-c improves insulin sensitivity, enhances glycolysis, reduces oxidative stress, and shows protective effects in models of metabolic syndrome, aging, and ischemia-reperfusion injury8135146.
While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, MOTS-c is a 16-amino-acid mitochondrial-derived peptide that translocates to the nucleus under metabolic stress and regulates glucose and lipid metabolism largely via activation of AMPK and modulation of mTOR and folate-cycle–linked pathways854140146.
BPC-157 is 15 amino acids long, whereas MOTS-c is longer as it has a length of 16 amino acids. BPC-157 is made up of a sequence of Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine. MOTS-c is made up of a sequence of Methionine, Arginine, Tryptophan, Glutamine, Glutamic acid, Methionine, Glycine, Tyrosine, Isoleucine, Phenylalanine, Tyrosine, Proline, Arginine, Lysine, Leucine, Arginine.
BPC-157
VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11
MOTS-c
BPC-157
Not assigned in the current dataset.
MOTS-c
MT-RNR1